A simple method for evaluating dengue vaccine effectiveness in mice based on levels of viremia caused by intraperitoneal injection of infected culture cells
- PMID: 19464557
- DOI: 10.1016/j.vaccine.2009.03.083
A simple method for evaluating dengue vaccine effectiveness in mice based on levels of viremia caused by intraperitoneal injection of infected culture cells
Abstract
A simple dengue vaccine evaluation system was established using a model of dengue type 2 virus (DENV2) infection in immunocompetent mice. Mice are usually non-permissive hosts, and artificial viremia was therefore created by intraperitoneal injection of K562 cells infected with DENV2. Plasma virus titers were approximately 4-5log(10) focus-forming units/ml at 10h after injection of 1x10(7) K562 cells into ICR, ddY and BALB/c mice. ICR mice immunized with an experimental vaccine against DENV2 showed reduced levels of viremia, associated with neutralizing antibody titers. Similarly, ICR mice passively immunized with purified IgG fractions of monoclonal antibodies possessing neutralizing activities also had reduced levels of viremia. However, the degree of viremia reduction differed according to the antibody species. Although some mice developed neurologic symptoms and/or died within 21 days of K562 injection, viremia reduction was considered to be a reliable indicator of the protective capacities of candidate dengue vaccines.
Similar articles
-
Dengue tetravalent DNA vaccine increases its immunogenicity in mice when mixed with a dengue type 2 subunit vaccine or an inactivated Japanese encephalitis vaccine.Vaccine. 2007 Jan 22;25(6):1076-84. doi: 10.1016/j.vaccine.2006.09.059. Epub 2006 Oct 2. Vaccine. 2007. PMID: 17084490
-
Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.Virology. 2002 Jun 20;298(1):146-59. doi: 10.1006/viro.2002.1462. Virology. 2002. PMID: 12093182
-
Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1.Virol J. 2007 Feb 28;4:23. doi: 10.1186/1743-422X-4-23. Virol J. 2007. PMID: 17328799 Free PMC article.
-
Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development.Vaccine. 2009 Jan 14;27(3):355-68. doi: 10.1016/j.vaccine.2008.10.086. Epub 2008 Nov 18. Vaccine. 2009. PMID: 19022321 Review.
-
Dengue vaccine: opportunities and challenges.IDrugs. 2008 Jan;11(1):42-5. IDrugs. 2008. PMID: 18175262 Review.
Cited by
-
Dengue transmission model by means of viremic adult immuno-competent mouse.Parasit Vectors. 2014 Mar 31;7:143. doi: 10.1186/1756-3305-7-143. Parasit Vectors. 2014. PMID: 24685121 Free PMC article.
-
Mouse models to study dengue virus immunology and pathogenesis.Front Immunol. 2014 Apr 10;5:151. doi: 10.3389/fimmu.2014.00151. eCollection 2014. Front Immunol. 2014. PMID: 24782859 Free PMC article. Review.
-
Non-Human Primate Models of Dengue Virus Infection: A Comparison of Viremia Levels and Antibody Responses during Primary and Secondary Infection among Old World and New World Monkeys.Pathogens. 2020 Mar 27;9(4):247. doi: 10.3390/pathogens9040247. Pathogens. 2020. PMID: 32230836 Free PMC article. Review.
-
Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice.Sci Rep. 2016 Jul 29;6:30648. doi: 10.1038/srep30648. Sci Rep. 2016. PMID: 27470096 Free PMC article.
-
The successful induction of T-cell and antibody responses by a recombinant measles virus-vectored tetravalent dengue vaccine provides partial protection against dengue-2 infection.Hum Vaccin Immunother. 2016 Jul 2;12(7):1678-89. doi: 10.1080/21645515.2016.1143576. Epub 2016 Feb 22. Hum Vaccin Immunother. 2016. PMID: 26901482 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical